CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Compass Therapeutics, Inc. (CMPX) is rated D+ (1.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Revisions (F). The rating has held at D+ for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B+ (3.7) | D+ (1.5) | C- (1.9) | D- (0.8) | F (0.0) | D+ (1.6) |
| 2026-11-04 | B+ (3.7) | D+ (1.6) | C (2.2) | D- (0.8) | F (0.0) | D+ (1.7) |
| 2026-10-28 | B+ (3.7) | D+ (1.6) | C (2.2) | D- (0.9) | F (0.0) | D+ (1.7) |
| 2026-10-21 | B+ (3.7) | D+ (1.6) | C (2.2) | D- (0.8) | F (0.0) | D+ (1.7) |
| 2026-10-14 | B+ (3.7) | D+ (1.6) | C (2.2) | D- (0.8) | F (0.0) | D+ (1.7) |